MA32563B1 - Dabigatran pour cathétérisme cardiaque de chirurgie percutanée - Google Patents

Dabigatran pour cathétérisme cardiaque de chirurgie percutanée

Info

Publication number
MA32563B1
MA32563B1 MA33616A MA33616A MA32563B1 MA 32563 B1 MA32563 B1 MA 32563B1 MA 33616 A MA33616 A MA 33616A MA 33616 A MA33616 A MA 33616A MA 32563 B1 MA32563 B1 MA 32563B1
Authority
MA
Morocco
Prior art keywords
dabigatran
percutaneous surgery
catheterism
cardiac
cardiac catheterism
Prior art date
Application number
MA33616A
Other languages
Arabic (ar)
English (en)
Inventor
Paul A Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41258283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32563(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32563B1 publication Critical patent/MA32563B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne une nouvelle utilisation du dabigatran étéxilate de formule (i) éventuellement sous la forme de ses sels pharmaceutiquement acceptables ainsi que de nouvelles formulations médicamenteuses pouvant être utilisées à cette fin.
MA33616A 2008-08-19 2011-02-15 Dabigatran pour cathétérisme cardiaque de chirurgie percutanée MA32563B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9001808P 2008-08-19 2008-08-19
PCT/EP2009/060592 WO2010020602A1 (fr) 2008-08-19 2009-08-17 Dabigatran pour cathétérisme cardiaque de chirurgie percutanée

Publications (1)

Publication Number Publication Date
MA32563B1 true MA32563B1 (fr) 2011-08-01

Family

ID=41258283

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33616A MA32563B1 (fr) 2008-08-19 2011-02-15 Dabigatran pour cathétérisme cardiaque de chirurgie percutanée

Country Status (19)

Country Link
US (1) US20110301201A1 (fr)
EP (1) EP2328580A1 (fr)
JP (1) JP2012500245A (fr)
KR (1) KR20110044230A (fr)
CN (1) CN102123707A (fr)
AR (1) AR073077A1 (fr)
AU (1) AU2009284217A1 (fr)
BR (1) BRPI0917507A2 (fr)
CA (1) CA2734794A1 (fr)
CL (1) CL2011000361A1 (fr)
CO (1) CO6290686A2 (fr)
EA (1) EA201100358A1 (fr)
EC (1) ECSP11010825A (fr)
IL (1) IL210005A0 (fr)
MA (1) MA32563B1 (fr)
MX (1) MX2011001612A (fr)
NZ (1) NZ591108A (fr)
TW (1) TW201022235A (fr)
WO (1) WO2010020602A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510072A (ja) 2008-11-11 2013-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法
EP2542224B1 (fr) * 2010-03-01 2014-08-13 Ratiopharm GmbH Composition pharmaceutique à voie orale contenant d'éxilate de dabigatrane
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CN103420984B (zh) * 2012-05-24 2015-07-08 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420982B (zh) * 2012-05-24 2015-07-08 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420985B (zh) * 2012-05-24 2015-09-23 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103524559B (zh) * 2012-07-05 2016-09-28 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103539779B (zh) * 2012-07-13 2016-12-21 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途
EP2900652A2 (fr) * 2012-09-28 2015-08-05 Ranbaxy Laboratories Limited Procédé de préparation d'étéxilate de dabigatran ou d'un sel pharmaceutiquement acceptable de cette substance
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
CN113164765B (zh) 2018-07-13 2026-03-20 维颂国际公司 凝血酶抑制剂、制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101005716B1 (ko) * 2002-03-07 2011-01-05 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
WO2006045756A1 (fr) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Utilisation de dipyridamole en association avec des antithrombotiques pour traiter et prevenir des maladies thromboemboliques
CA2657266A1 (fr) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh Nouvelles indications portant sur les inhibiteurs directs de la thrombine dans le domaine cardiovasculaire
CL2007002067A1 (es) * 2006-07-17 2008-01-25 Boehringer Ingelheim Int Uso de dabigatran etexilato, inhibidores directos de la trombina, para el tratamiento y/o profilaxis en niños de enfermedades tales como infarto cerebral no hemorragico, infarto de miocardio, arritmia, trombosis venosa central, entre otras.
WO2008043759A1 (fr) * 2006-10-10 2008-04-17 Boehringer Ingelheim International Gmbh Sels physiologiquement acceptables de l'ester éthylique de l'acide 3-[(2-{[4-(hexyloxycarbonylamino-imino-méthyl)-phénylamino]-méthyl}-1-méthyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionique.

Also Published As

Publication number Publication date
EA201100358A1 (ru) 2011-10-31
CO6290686A2 (es) 2011-06-20
EP2328580A1 (fr) 2011-06-08
AU2009284217A1 (en) 2010-02-25
JP2012500245A (ja) 2012-01-05
AR073077A1 (es) 2010-10-13
MX2011001612A (es) 2011-03-04
CN102123707A (zh) 2011-07-13
TW201022235A (en) 2010-06-16
CL2011000361A1 (es) 2011-06-17
IL210005A0 (en) 2011-02-28
KR20110044230A (ko) 2011-04-28
WO2010020602A1 (fr) 2010-02-25
ECSP11010825A (es) 2011-03-31
NZ591108A (en) 2012-11-30
BRPI0917507A2 (pt) 2015-11-17
CA2734794A1 (fr) 2010-02-25
US20110301201A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA29909B1 (fr) Derives de pyridazine
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
UA105911C2 (uk) Сульфонамідні похідні
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
PA8658301A1 (es) Derivados fusionados de pirazol y metodos de tratamiento de trastornos metabolicos con estos
MA33721B1 (fr) Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA30781B1 (fr) Inhibiteur de kinase
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
UA107784C2 (en) Inhibitor of melanin production
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA29775B1 (fr) Derives de pyrazolone
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa